Rigel Pharmaceuticals Lands Exclusive Global Deal for Breakthrough Breast Cancer Drug Veppanu
Arvinas & Pfizer partner with Rigel to launch Veppanu, a new oral breast cancer drug showing strong results and better survival.
/ 41 items
#PFE↓
Novavax Smashes Q1 2026 Revenue Expectations with Big Vaccine Tech Deals
Novavax beat forecasts with $140M revenue, boosted by vaccine tech deals, new partnerships, and strong cash position.
FDA Approves First-Ever PROTAC Drug Veppanu for Advanced Breast Cancer with ESR1 Mutation
FDA approved Pfizer/Arvinas Veppanu pill for advanced breast cancer with ESR1 mutation, helping hormone-resistant cases.
Pfizer Delays Generic Vyndamax Until 2031 – Great News for BridgeBio’s Attruby
Pfizer extends Vyndamax patent to 2031, delaying generics and giving BridgeBio more time to grow its rival heart drug without pressure.
Pfizer and Valneva Lyme Vaccine Shows Over 70% Efficacy in Phase 3 Trial — But Misses Main Goal
Pfizer and Valneva reported their Lyme disease vaccine demonstrated 73.2% efficacy in the Phase 3 VALOR trial. While it missed the primary statistical target due to fewer cases, strong results support upcoming regulatory submissions.
BioNTech Co-Founders Ugur Sahin and Özlem Türeci Launch New mRNA Biotech as Company Sharpens Focus on Cancer Pipeline
BioNTech co-founders Ugur Sahin & Özlem Türeci are starting an independent next-gen mRNA company by end-2026. BioNTech keeps focus on oncology (15 Phase 3 trials).